On April 25, 2023, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced interim results from the ongoing Phase 1/2 clinical trial of ARO-RAGE, which is being developed to reduce production of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results